What 3,000+ Lawsuits Reveal About Ozempic and Wegovy Side Effects Nobody Warns You About

If you're taking semaglutide, whether as Ozempic for diabetes or Wegovy for weight loss—you need to understand the complete side effect profile. Not just the common gastrointestinal issues your doctor mentioned, but also the serious complications that have led to over 3,000 federal lawsuits as of February 2026.

Here's the reality nobody wants to talk about: While millions of people tolerate semaglutide well, a subset of users experience severe, sometimes permanent complications. Gastroparesis (stomach paralysis) that requires feeding tubes. NAION (sudden vision loss) that's irreversible. Intestinal obstruction that sends people to the emergency room.

These aren't theoretical risks. They're documented injuries currently being litigated in federal court (MDL 3094). In January 2025, the FDA updated Ozempic's label to state it's "not recommended in patients with severe gastroparesis", an acknowledgment that the drug can worsen or potentially cause this condition.

This guide covers everything you need to know about semaglutide side effects, from the common (44% get nausea) to the serious (4-7x increased NAION risk) to the legal context (what those 3,000 lawsuits mean for you). We'll explain why Ozempic and Wegovy have different side effect profiles despite being the same drug, how to recognize warning signs of serious complications, and what actually works to manage symptoms.

No sugar-coating. No manufacturer talking points. Just the clinical data, the emerging safety concerns, and the practical information you need to make informed decisions.

⚠️ A quick note: This article is for informational purposes only and is not a substitute for medical advice. If you're experiencing severe side effects, contact your healthcare provider immediately. The information about lawsuits is provided for context, not legal advice.

Understanding Semaglutide: One Drug, Multiple Brands

Before diving into side effects, let's clarify what we're talking about:

‍Semaglutide is the active ingredient in three FDA-approved brands:

Same active ingredient, different dosing strategies:

• Ozempic typically uses 0.5 mg, 1 mg, or 2 mg maintenance doses
• Wegovy escalates to 2.4 mg (higher than most Ozempic doses)
• Rybelsus uses daily dosing instead of weekly

Why this matters for side effects:

• Higher doses = more frequent and intense side effects (Wegovy users report nausea at 44% vs Ozempic at 15-20%)
• Weekly injections vs daily pills affect how side effects manifest (injection peaks vs steady-state)
• The indication matters (diabetes patients have pre-existing conditions that affect risk profile)

Throughout this article, "semaglutide" refers to all three brands unless otherwise specified.

Common Side Effects: What Most Users Experience

These side effects occur in ≥5% of users across clinical trials. They're considered "common" and are usually manageable.

Nausea (15-44% Depending on Dose/Brand)

Nausea is the #1 most reported side effect of semaglutide.

Prevalence by brand:

• Ozempic: 15-20% (lower doses)
• Wegovy: 44% (higher 2.4 mg dose)
• Rybelsus: 10-15% (daily dosing)

Why it happens: Semaglutide slows gastric emptying, food sits in your stomach longer, creating persistent fullness that often manifests as nausea.

Timeline:

• Peak intensity: Weeks 1-8, especially during dose increases
• Improvement: ~70% see significant improvement by week 20
• Persistent cases: ~30% continue experiencing nausea long-term

Management strategies:

• Eat smaller, more frequent meals (5-6 small vs 3 large)
• Avoid high-fat, greasy, spicy foods
• Stay upright 30+ minutes after eating
• Ginger (tea, candies, supplements)
• Anti-nausea medication (ondansetron, ask your doctor)

Vomiting (9-24%)

Ozempic: 9% | Wegovy: 24% | Rybelsus: 8%

Vomiting is less common than nausea but still affects up to a quarter of Wegovy users. It typically occurs during dose escalation.

When to worry:

• Persistent vomiting (24+ hours): Risk of dehydration and kidney damage
• Vomiting blood or coffee-ground material: Emergency, call 911
• Unable to keep down fluids: Seek medical attention

⚠️ Reality Check: The CDC reported over 25,000 ER visits in 2023 linked to semaglutide users, many for severe vomiting and dehydration. This isn't just "minor nausea", it can escalate to medical emergencies.

Diarrhea (30% Wegovy, 8-12% Ozempic)

Diarrhea affects nearly a third of Wegovy users and is dose-dependent.

Management:

• Aggressive hydration (8+ glasses daily)
• BRAT diet when severe (bananas, rice, applesauce, toast)
• Avoid caffeine and high-fat foods
• Loperamide (Imodium) short-term if needed

Constipation (24% Wegovy, 5-7% Ozempic)

Paradoxically, semaglutide causes both diarrhea AND constipation in different users. About a quarter of Wegovy users experience constipation.

Why both happen: Slowed gastric emptying affects the entire GI tract differently in different people, some experience accelerated transit (diarrhea), others slowed (constipation).

‍Management:

• Gradual fiber increase (add 5g/week)
• Stay hydrated
• Stool softeners (docusate sodium)
• Magnesium supplements (check with doctor)

Other Common Side Effects (5-20%)

Serious Side Effects: What You Really Need to Know

These are the complications driving the 3,191 federal lawsuits as of February 2026. They're rare, but the consequences can be severe and permanent.

Gastroparesis (Stomach Paralysis) , The $3 Billion Lawsuit

What it is: Gastroparesis is a condition where the stomach muscles don't contract normally, causing food to remain in the stomach for extended periods without mechanical obstruction.

How semaglutide may cause it: Semaglutide activates GLP-1 receptors that regulate gastric motility. The question being litigated: Does slowing gastric emptying sometimes tip into permanent gastroparesis?

Prevalence: The exact rate is unknown (and contested in litigation). What we know:

• Documented cases: Hundreds of lawsuits alleging gastroparesis
• FDA reports: Dozens of gastroparesis cases in FDA adverse event database
• 2023 research: Semaglutide users experienced gastroparesis nearly 3x more often than users of other weight-loss drugs

Symptoms:

• Persistent nausea and vomiting
• Feeling full after eating very little
• Bloating and abdominal pain
• Weight loss (unintentional)
• Blood sugar fluctuations (in diabetics)

Diagnosis controversy: A major point of contention in the lawsuits: Does gastroparesis diagnosis require a gastric emptying study?

• Defendants argue: Yes, gold-standard testing required
• Plaintiffs argue: Clinical diagnosis (symptoms + EGD findings) is sufficient

Treatment:

• Stop semaglutide (symptoms often improve but may not fully resolve)
• Dietary changes (small, frequent, low-fat, low-fiber meals)
• Prokinetic medications (metoclopramide)
• Severe cases: Feeding tubes, gastric electrical stimulation

January 2025 Label Update: The FDA updated Ozempic's label to state it's "not recommended in patients with severe gastroparesis." This doesn't say semaglutide causes gastroparesis, but acknowledges it shouldn't be used in patients who already have severe gastroparesis.

NAION (Sudden Vision Loss) , The Emerging Crisis

What it is: Non-arteritic anterior ischemic optic neuropathy (NAION) is sudden, painless vision loss caused by reduced blood flow to the optic nerve. It's permanent and irreversible.

The research:

• July 2024 JAMA Ophthalmology study: Semaglutide users had 4-7x higher risk of NAION compared to users of other diabetes/weight-loss drugs
• European Medicines Agency (EMA) 2025: Concluded semaglutide doubles NAION risk
• June 2025 JAMA follow-up: Linked semaglutide to additional vision injuries beyond NAION

Numbers:

• Risk in diabetic patients on semaglutide: 6.7%
• Risk in diabetic patients on other medications: 0.89%
• Over 140 NAION lawsuits filed as of February 2026

Symptoms:

• Sudden vision loss (often noticed upon waking)
• Painless (distinguishes from other eye emergencies)
• Usually one eye (but can affect both)
• Described as blurring, cloudiness, or "curtain coming down"
• Flashes of light, sudden floaters

Who's at risk:

• People with diabetes (already at higher vascular risk)
• People with existing cardiovascular disease
• People over 50
• BUT: Some cases occurring in relatively healthy users without prior eye problems

Treatment: There is no effective treatment for NAION. Vision loss is permanent. This is why it's generating so much litigation attention, the consequences are catastrophic and irreversible.

Current FDA status:

• No black box warning yet (as of February 2026)
• Medical professionals pushing for black box warning
• NAION lawsuits now have their own "Vision Injury Track" within MDL 3094

⚠️ Reality Check: The EMA has concluded that semaglutide doubles NAION risk. While the absolute risk is still low, the sheer number of people taking semaglutide means thousands could be affected. If you experience sudden vision changes, stop semaglutide immediately and seek emergency eye care.

Pancreatitis (0.2-0.5%)

Acute pancreatitis (inflammation of the pancreas) has been observed in semaglutide clinical trials and post-market surveillance.

Symptoms:

• Severe upper abdominal pain that doesn't go away
• Pain radiating to your back
• Nausea and vomiting
• Rapid heartbeat
• Fever

What to do: If you suspect pancreatitis, stop semaglutide immediately and seek emergency care. Do not restart if pancreatitis is confirmed.

FDA reports: Cases of fatal and non-fatal hemorrhagic or necrotizing pancreatitis have been reported.

Ileus & Intestinal Obstruction

Ileus is when intestinal contractions temporarily stop, causing food, gas, and fluids to back up.

Intestinal obstruction is physical blockage of the intestines.

Both have been reported in semaglutide users and are part of the MDL 3094 litigation.

Symptoms:

• Severe bloating
• Inability to pass gas or stool
• Severe abdominal pain and cramping
• Vomiting

Treatment: Often requires hospitalization, sometimes surgery.

FDA action: In September 2023, the FDA added ileus warnings to Ozempic's label.

Thyroid C-Cell Tumors (Boxed Warning)

Semaglutide carries an FDA boxed warning, the most serious type, for thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).

What we know:

• Semaglutide caused thyroid tumors in rodent studies
• Unknown if it causes thyroid cancer in humans
• No confirmed human cases directly attributed to semaglutide

Contraindications:

• Personal or family history of MTC
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Warning signs:

• Lump or swelling in neck
• Hoarseness
• Trouble swallowing
• Shortness of breath

Hypoglycemia (Low Blood Sugar)

Who's at risk: People with type 2 diabetes taking semaglutide with insulin or sulfonylureas.

Risk by population:

• Diabetics on semaglutide + insulin/sulfonylureas: 6-10%
• Non-diabetics on semaglutide: Virtually no risk

Symptoms:

• Shakiness, sweating
• Confusion, irritability
• Rapid heartbeat
• Dizziness, hunger

Prevention: Your doctor may need to reduce insulin or sulfonylurea doses when starting semaglutide.

Acute Kidney Injury

Dehydration from severe vomiting/diarrhea can lead to kidney damage.

2025 FDA data analysis: Significant number of acute kidney injury cases linked to semaglutide.

Warning signs:

• Swelling (legs, ankles, feet)
• Urinating less than usual
• Feeling tired or short of breath
• Confusion

Prevention: Aggressive hydration, especially during first few months. If vomiting/diarrhea persists, contact doctor immediately.

Gallbladder Disease

Rapid weight loss increases gallstone risk. Semaglutide accelerates weight loss, which increases cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation).

Rates:

• Cholelithiasis: 1.6% (Wegovy adults), 3.8% (Wegovy adolescents)
• Cholecystitis: 0.6% (adults), 0.8% (adolescents)

Symptoms:

• Upper right abdominal pain
• Fever
• Clay-colored stools
• Jaundice (yellowing of skin/eyes)

Anesthesia Complications & Pulmonary Aspiration

This is a newer concern getting significant attention in the medical community and litigation.

The problem: Semaglutide slows gastric emptying so much that food can remain in the stomach for 24+ hours. If someone undergoes surgery with retained gastric contents, there's risk of pulmonary aspiration (stomach contents entering the lungs) during anesthesia.

American Society of Anesthesiologists recommendation: Hold semaglutide 1 week before elective surgery to reduce aspiration risk.

Lawsuits: Multiple cases alleging pulmonary aspiration during surgery while on semaglutide.

Ozempic vs Wegovy: Do Side Effects Differ?

They're the same drug, but side effect profiles differ due to dosing:

Key insight: Wegovy's higher 2.4 mg dose produces more frequent and intense side effects across the board. This is why Wegovy users are more likely to experience severe GI issues and why many of the gastroparesis lawsuits involve Wegovy specifically.

The Legal Context: What 3,000+ Lawsuits Mean

As of February 2026, 3,191 federal lawsuits are pending in MDL 3094 (In re: Glucagon-like Peptide-1 Receptor Agonists Products Liability Litigation) in the Eastern District of Pennsylvania.

Allegations:

• Failure to warn: Manufacturers knew or should have known about gastroparesis and NAION risks but failed to provide adequate warnings
• Design defect: The drug's mechanism inherently creates these risks
• Negligence: Inadequate post-market surveillance and safety monitoring

Breakdown by injury type:

• Gastroparesis/GI injuries: Original wave of lawsuits (2,800+)
• NAION vision loss: New wave getting significant attention (140+, separate "Vision Injury Track")
• Other: Pancreatitis, kidney injury, DVT/pulmonary embolism

Nearly 500 deaths in the U.S. linked to semaglutide medications reported in FDA Adverse Event Reporting System (per November 2024 master complaint).

Status:

• No settlements yet (as of February 2026)
• Bellwether trials expected 2026-2027
• Judge Karen S. Marston presiding

What this means for you: These lawsuits don't mean semaglutide is "unsafe" for everyone—millions tolerate it well. But they reveal serious injuries are happening at rates concerning enough to drive mass litigation. The legal system is determining whether manufacturers provided adequate warnings.

🤔 Why This Matters: The fact that thousands of people have filed lawsuits doesn't mean semaglutide will be pulled from the market. But it does mean the risk-benefit calculation is being scrutinized, and label updates are likely. Stay informed about emerging safety data.

Less Common But Important Side Effects

Hair Loss (3% Wegovy, Underreported in Ozempic)

Telogen effluvium (stress-induced hair shedding) from rapid weight loss. See our detailed Wegovy side effects article for management strategies.

Diabetic Retinopathy Worsening (1.6% of Diabetic Patients)

Rapid blood sugar improvement can paradoxically worsen existing diabetic eye disease. Requires monitoring.

Increased Heart Rate

Semaglutide increases resting heart rate by 1-4 bpm average. 41% experienced 10-19 bpm increases at some point.

Malnutrition & Wernicke's Encephalopathy

Severe, persistent vomiting can lead to vitamin deficiencies. Cases of Wernicke's encephalopathy (thiamine deficiency causing brain damage) have been reported in lawsuits.

Side Effects Timeline: When to Expect What

Management Strategies: What Actually Works

For GI Side Effects

Comprehensive approach:

1. Eat differently: 5-6 small meals, avoid triggers (high-fat, spicy)
2. Timing: Inject at night to sleep through peak nausea
3. Hydration: 8+ glasses daily (non-negotiable)
4. Medications: Ondansetron for nausea, loperamide for diarrhea, stool softeners for constipation
5. Slow titration: Extra 4 weeks at each dose if needed

For Suspected Gastroparesis

If you have persistent symptoms:

1. Document everything: Food intake, vomiting episodes, timing
2. Upper endoscopy: Request EGD if symptoms persist 8+ weeks
3. Consider gastric emptying study: Gold standard for diagnosis
4. Discuss stopping semaglutide: Symptoms often improve (but may not fully resolve)

For Vision Protection

Proactive monitoring:

1. Baseline eye exam: Before starting semaglutide, especially if diabetic
2. Annual follow-ups: With ophthalmologist
3. Report any changes immediately: Sudden vision loss, flashes, floaters
4. Know warning signs: Painless vision loss in one eye, especially upon waking

For Surgery Planning

Critical steps:

1. Inform all providers you're on semaglutide
2. Hold medication 1 week before elective surgery (per ASA guidance)
3. Verify gastric emptying before anesthesia if possible
4. Consider rapid sequence intubation protocols

When to Stop Semaglutide Immediately

Call 911 or go to ER if you experience:

• Severe abdominal pain that doesn't go away
• Vomiting blood or coffee-ground material
• Sudden vision loss or severe vision changes
• Difficulty breathing or severe allergic reaction
• Severe chest pain

‍Contact your doctor immediately if you experience:

• Persistent vomiting for 24+ hours
• Signs of severe dehydration (dizziness, confusion, dark urine)
• Lump or swelling in your neck
• Persistent upper right abdominal pain (gallbladder)
• Signs of pancreatitis (severe upper stomach pain radiating to back)

‍Discuss stopping with your doctor if:

• GI side effects significantly impact quality of life after 3+ months
• You've tried all management strategies without improvement
• You develop suspected gastroparesis symptoms
• You're scheduled for surgery

Can I take semaglutide if I have pre-existing gastroparesis? 

No. As of January 2025, Ozempic's label states it's "not recommended in patients with severe gastroparesis."

How long should I hold semaglutide before surgery? 

The American Society of Anesthesiologists recommends holding semaglutide 1 week before elective surgery to reduce aspiration risk.

The Bottom Line

Semaglutide is a powerful medication that helps millions manage diabetes and lose weight. But it's not without serious risks, risks that are now being scrutinized in over 3,000 federal lawsuits.

The numbers:

• Common side effects are very common: 44% get nausea, 30% get diarrhea
• Serious side effects are rare but devastating: Gastroparesis requiring feeding tubes, NAION causing permanent blindness
• 3,191 lawsuits pending alleging failure to warn about these risks
• Nearly 500 deaths reported in FDA adverse event database

The emerging concerns:

• Gastroparesis: May not fully resolve even after stopping medication
• NAION: 4-7x increased risk, permanent vision loss
• EMA conclusion: Semaglutide doubles NAION risk
• Anesthesia complications: Pulmonary aspiration from retained gastric contents

What you need to do:

1. Monitor for warning signs of serious complications (persistent vomiting, sudden vision loss, severe abdominal pain)
2. Inform all healthcare providers you're on semaglutide, especially before surgery
3. Get baseline and annual eye exams if diabetic
4. Document persistent symptoms that don't improve, they may indicate gastroparesis
5. Stay informed about label updates and emerging safety data

The fact that over 3,000 people have filed lawsuits doesn't mean you'll experience these complications. But it does mean the risks are real, documented, and in some cases, more serious than initially understood.

Only you and your doctor can decide whether semaglutide's benefits outweigh its risks for your specific situation. But you deserve to make that decision with complete information, not just the manufacturer's talking points.

References

‍